Protocol Ledger

NCT04891289 · Phase II · RECRUITING

Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery

Interventional Phase II clinical trial protocol NCT04891289 sponsored by Memorial Sloan Kettering Cancer Center in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-05-07 Enrollment: 164 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04891289
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)164 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04891289
Protocol FieldVerified Registry Value
NCT IdentifierNCT04891289
Consolidated Lead SponsorMemorial Sloan Kettering Cancer Center
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment164 participants (ESTIMATED)
Registered Start Date2021-05-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Memorial Sloan Kettering Cancer Center across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI